Clinical trials: Viral Load
Hiv
Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program
The Ryan White HIV/AIDS Program (RWHAP) for low-income people with HIV (PWH) is a key resource for reducing HIV health disparities and scaling up evidence-based interventions.
- Trial name
- D2S (NCT05140421)
- Testing
- Data to Suppression (D2S), Usual practice
- Where
- 27 sites in United States
- Volunteers
- 1,494 people
- Sponsor
- City University of New York
Covid19
Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients
Randomized, double-blind, placebo-controlled pilot study to evalaute viral load in saliva of COVID19+ patients using quantitative PCR, before and after use of active or placebo rinses
- Trial name
- NCT04563689
- Testing
- CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)
- Where
- Colombia
- Volunteers
- 23 people
- Sponsor
- Dentaid SL
HIV, Patient Compliance
Intervention to Improve Engagement in Care Among Newly Diagnosed HIV-positive Men
The study involves delivering one of two interventions - either Promoting Action Towards Health (PATH) or Personalized Cognitive Counseling (PCC) - to 440 men who have sex with men (MSM) who have recently been diagnosed with HIV…
- Trial name
- NCT01559805
- Testing
- Positive Choices, Personalized Cognitive Counseling
- Where
- 4 sites in United States
- Volunteers
- 202 people
- Sponsor
- Columbia University
Alcohol Drinking, Alcohol Use Norms
Formative Phase of Reducing Hazardous Alcohol Use & HIV Viral Load
This study is the Formative Phase of a larger study; once this phase is completed, enrollment into the randomized controlled trial (RCT Phase) will begin.
- Conditions
- Alcohol Drinking, Alcohol Use Norms, Alcohol Use Among ART Clients
- Trial name
- F-REDART (NCT02153216)
- Where
- Vietnam
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Evaluation of Low-dose Darunavir in a Switch Study
This is a switch study to assess the non-inferiority (in terms of efficacy and safety) of darunavir (boosted with ritonavir, DRV/r 400mg/100mg daily) when compared with lopinavir (boosted with ritonavir, LPV/r total dose…
- Trial name
- DRV (NCT02671383)
- Testing
- Darunavir, Lopinavir
- Where
- South Africa
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Willem Daniel Francois Venter
HIV Infections
Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects
To compare the proportion of patients in the 2 zidovudine (ZDV)-containing arms who have a plasma HIV RNA concentration below the limit of detection (defined as 500 copies/ml or less) at Weeks 20 and 24 [AS PER AMENDMENT 8/24/98…
- Trial name
- NCT00000882
- Testing
- Indinavir sulfate, Delavirdine mesylate, Lamivudine
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)
- Trial name
- NCT00634959
- Testing
- Maraviroc (UK-427,857)
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- ViiV Healthcare
HIV Infections
The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs
To compare the safety, tolerance, durability of the viral load response and the antiviral activity of the 1592U89/zidovudine(ZDV)/lamivudine (3TC) regimen vs. ZDV/3TC regimen.
- Trial name
- NCT00002391
- Testing
- Abacavir sulfate, Lamivudine, Zidovudine
- Where
- 30 sites in United States
- Sponsor
- Glaxo Wellcome
HIV-1 Infection
Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL
This multicenter, international, non randomized (single arm), open, phase II trial aims to evaluate the capacity of the dual combination raltegravir/etravirine to maintain virological success in virologically suppressed HIV-1…
- Trial name
- NCT02212379
- Testing
- raltegravir and etravirine
- Where
- 19 sites in France, Spain
- Volunteers
- 170 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Lopinavir/r Monotherapy as Maintenance Therapy After Long Term Viral Suppression
1. Objectives Primary To investigate the possibility of maintaining virological suppression of HIV in infected patients, switching them to LPV/r as the only antiretroviral agent To assess the immunological response in patients…
- Trial name
- NCT00160849
- Testing
- Lopinavir/r
- Where
- 2 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Universidade Federal do Rio de Janeiro
HIV Infections
Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load
Antiretroviral therapy (ART) can reduce HIV to very low levels in the blood, but it cannot cure HIV infection because a small amount of virus remains in cells as a hidden (latent) form.
- Trial name
- NCT01933594
- Testing
- Romidepsin
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Zinc Deficiency, Sars-CoV-2 Infection
Zinc Supplementation Impact in Acute COVID-19 Clinical Outcomes
Infections with SARS-CoV-2 result in a systemic disease with a variety of outcomes, from no symptoms to severe and diverse pathologies.
- Trial name
- MARZINC (NCT05778383)
- Testing
- Zinc Acetate
- Where
- Spain
- Volunteers
- 75 people
- Sponsor
- Parc de Salut Mar
HIV Infections
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
The mouth may play an important part in monitoring HIV progression. Mucosal lesions of the mouth are often the first sign of infection and their development in already diagnosed individuals indicates disease progression.
- Trial name
- NCT00959413
- Where
- 6 sites in United States, Haiti
- Volunteers
- 328 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV/AIDS
Reaching 90% HIV Suppression: The Role of POC Viral Load Monitoring in Nigeria
The UNAIDS 90-90-90 goals represents an ambitious strategy to end the acquired immunodeficiency syndrome (AIDS) epidemic by 2020 [UNAIDS, 2015].
- Trial name
- POC (NCT03533868)
- Testing
- Point-of-care viral load monitoring test
- Where
- 2 sites in Nigeria
- Volunteers
- 543 people
- Sponsor
- Harvard School of Public Health (HSPH)
HIV-2 Infection
RESIST-2: 2nd-line ART for HIV-2 Infection
Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance informed 2nd-line ARV implementation study.
- Trial name
- RESIST-2 (NCT03394196)
- Testing
- HIV-2 Genotypic Drug Resistance Testing using DBS, 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )
- Where
- 2 sites in Senegal
- Volunteers
- 152 people
- Sponsor
- University of Washington
Hepatitis B, HIV Infection
Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients
This study will evaluate the safety and effectiveness of adding the experimental drug adefovir dipivoxil to lamivudine for treating hepatitis B virus (HBV) infection in HIV-infected patients with liver cirrhosis.
- Trial name
- NCT00013702
- Testing
- Adefovir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, HIV Infections
Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration
This pilot study aims to evaluate Maraviroc intensification strategy during 24 weeks in HIV infected patients under efficient (CV< 50 cp/mL), controlled antiretroviral therapy (≥ 6 months) and uncompleted immune restoration…
- Trial name
- 145 MARIMUNO (NCT00944541)
- Testing
- maraviroc
- Where
- France
- Volunteers
- 60 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis C, Chronic
HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug Users in Brussels
The main objective of this study is to assess the interest (linkage to care) of the Cepheid GeneXpert HCV VL Fingerstick test in Brussels among drug users or former users in contact with the Réseau Hépatite C Bruxelles…
- Trial name
- NCT04610762
- Testing
- GeneXpert HCV VL Fingerstick test
- Where
- Belgium
- Volunteers
- 103 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
HIV Infections, Fatty Liver Disease
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
In HIV-infected people with metabolic fatty liver disease and liver fibrosis of any degree, as measured by non-invasive testing, antiretroviral treatment that includes rilpivinire for 18 months results in a slowing of progression…
- Trial name
- MAFALDA-R (NCT05898841)
- Testing
- Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundacion SEIMC-GESIDA
HIV Infections
Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
The purpose of this study is to determine the effect of treatment with Trizivir (TZV) plus efavirenz (EFV) or TZV alone on viral load (level of HIV in the blood).
- Trial name
- NCT00011895
- Testing
- Abacavir sulfate, Lamivudine and Zidovudine, Efavirenz
- Where
- 42 sites in United States
- Volunteers
- 400 people
- Sponsor
- GlaxoSmithKline